secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001104659-25-066520
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio gets FDA Orphan Drug Designation for MB-101 CAR T-cell therapy in astrocytomas and glioblastoma
--------------------------------------------------------------------------------

- FDA granted Orphan Drug Designation to MB-101 for recurrent diffuse/anaplastic astrocytoma and glioblastoma.
- Designation provides tax credits, fee waivers, and potential 7-year market exclusivity upon approval.
- Phase 1 trial showed 50% stable disease or better; two complete responses lasting 7.5 and 66+ months.
- Preclinical data support combining MB-101 with oncolytic virus MB-108 to improve efficacy.
- Company notes development of MB-109 program is contingent on raising additional funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000110465925066520/0001104659-25-066520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000110465925066520/tm2520081d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-066520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer